IBM three-lens brief
Evidence-based stock research on IBM. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 15.0pp over 30 days. · Trading at 11% of its 52-week range — deep in the lower band.
- Trading at 11% of its 52-week range — deep in the lower band.
- Underperforming SPY by 15.0pp over 30 days.
- Analyst mean target $279.68 — 20% above current (20 analysts).
- Debt-to-equity of 211.2 — balance-sheet-heavy.
IBM closed at $232.61 (+0.18%) as of 2026-05-04. Market cap: $218.63B. P/E (trailing) 20.6. Positives: analyst mean target $279.68 — 20% above current (20 analysts).. Concerns: trading at 11% of its 52-week range — deep in the lower band.; underperforming SPY by 15.0pp over 30 days.. Last quarter: Revenue $15.92B, net income $1.22B, free cash flow $13.08B.
Why three lenses on IBM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine IBMacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/IBM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath IBM brief"></iframe>